Structure-based drug design strategies often devise competitive Inhibitors that bind to certain enzyme active sites. For example saquinavir and Indinavir are designed HIV protease inhibitors that bind to the aspartate protease enzyme of HIV, which is required for the virus to produce functional proteins for further HIV infection. Which of the following statements are true about saquinavir and Indinavir? Choose one or more:
A. Very high local concentrations of proteins with Phe-Pro or Tyr-Pro peptide bonds would reduce the protease enzyme reaction vir and indinavir both have a component that mimics the natural Phe-Pro dipeptide substrate of aspartate
B. The removal of the phenyi ring (six-membered carbon ring containing three double bonds and no attached functional groups) on indinavir and saquinavir would likely affect their Inhibitory activity
C. Increasing concentrations of indinavir or saquinavir would result in a change in the a of the aspartate
D. Saquinav effectiveness of saquinavir and indinavir in limiting HiV's infectivity of new cells. protease enzyme reaction vir and indinavir both have a component that mimics the natural Phe-Pro dipeptide substrate of aspartate